Insys Therapeutics prices IPO at $8, at the low end of the revised range

Credit: Shutterstock photo

Insys Therapeutics, which markets an opioid and synthetic marijuana drug for cancer pain and CINV, raised $32 million by offering 4 million shares at $8, at low end of the range of $8 to $10. The company had previously filed to offer 4 million shares at a range of $16 to $18. Insys Therapeutics will list on the NASDAQ under the symbol INSY. Wells Fargo Securities and JMP Securities acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.